FDA Committee to Review Moderna's mRNA Flu Vaccine for Older Adults

An advisory committee to the Food and Drug Administration is scheduled to meet today. The committee will evaluate the safety and effectiveness of Moderna's MFLUSIVA, an mRNA-based influenza vaccine. This discussion is a crucial step in the potential approval process for the vaccine, intended for individuals aged 50 and above.